Ip-Cure-B and Thervacb Researchers Join Forces to Accelerate Hepatitis B Cure Research.
There are two experts in virology, immunology and clinical hepatitis for joint-research projects are started working towards to cure hepatitis B seriously.
Those are:
1) IP-cure-B: Take care of your health and
2) TherVacB: A therapeutic vaccine to cure Hepatitis B.
However, both of the research teams are jointly going to tackle some of the major challenges in the therapy of chronic viral hepatitis B. This is the good news that, the two researchers have met to work together and go for a first round of strategic discussions in July 2023.
However, the two research projects share the common goal to achieve functional cure of hepatitis B. Their scientists are investigating in every aspect of the viral hepatitis B infection (HBV) and the HBV-mediated chronic disease.
The IP-cure-B has main motto to improve the cure rate in patients with chronic hepatitis B (CHB) with balancing immunomodulatory concepts. Immune intrusions are inspected mainly in two settings:
- 1) A pre-clinical model and
- 2) A proof-of-concept clinical study.
You can know the details in this video. Please click on the following video.
It is expected that, the innovations in immunotherapy will boost the strategic selection of the best combination for effective treatment in future clinical studies. On the other hand, TherVacB provides a novel curative treatment option that aims to break immune tolerance in chronic HBV infection.
